Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod

Ependymoma Clinical Trial

Official title:

Immunotherapy for Recurrent Ependymomas in Children Using Human Leukocyte Antigen (HLA)-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01795313
• Other study ID #: STUDY19100001
• Secondary ID: R01CA174858PRO12
• Status: Recruiting
• Phase: Phase 1
• Start date: August 2012
• Est. completion date: December 31, 2025

Study information

• Verified date: October 2023
• Source: University of Pittsburgh
• Contact: James Felker, MD
• Phone: 412-692-5055
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to see if vaccination with HLA-A2 restricted peptides, combined with the immunoadjuvant imiquimod is safe and can induce immune responses in children with recurrent ependymomas. Eligible patients are stratified by primary tumor location.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Months to 21 Years

Eligibility

Inclusion Criteria: All grades of ependymoma are eligible.

• Patients must have recurrent/progressive ependymoma that has progressed or recurred after initial adjuvant therapy.

• HLA-A2 positive based on flow cytometry performed at the University of Pittsburgh.

• Patients must have previously received standard initial therapy including attempted gross total resection, where safely feasible, and in appropriate circumstances (e.g., those older than one year at initial diagnosis, with non-metastatic tumors and at least microscopic residual disease), involved field fractionated radiation therapy (RT). Patients may have received re-irradiation but not to the index lesion within 4 weeks.

• Patients must be clinically stable and off or on low-dose (no more than 0.1 mg/kg/day, max 4 mg/day Dexamethasone) corticosteroid for at least one week prior to study registration.

• Patients must be = 12 months and <22 years of age at the time of study registration.

• Patients must have a performance status of = 70; (Karnofsky if > 16 years and Lansky if = 16 years of age).

• Patients may have non-bulky, asymptomatic metastatic disease.

• Males and females must agree to use effective birth control methods during the course of vaccination (from the first vaccine to two weeks after the last vaccine).

• Patients must be free of systemic infection requiring IV antibiotics at the time of registration and off IV antibiotics for at least 7 days prior to registration.

• Patients must have adequate organ function as measured by:

• Bone marrow: Absolute neutrophil count (ANC) > 1,000/µl; Platelets > 100,000/µl (transfusion independent); Absolute lymphocyte count (ALC) = 500/µl; Hemoglobin >8 g/dl (may be transfused).

• Hepatic: bilirubin = 1.5x institutional normal for age; serum glutamate pyruvate transaminase (SGPT) < 3x institutional normal

• Renal: Serum creatinine based on age or creatinine clearance or radioisotope glomerular filtration rate (GFR) > 70 ml/min/1.73 m²

• Patients must have recovered from the toxic effects of prior therapy and be at least 3 weeks from the last dose of standard cytotoxic chemotherapy or myelosuppressive biological therapy, at least one week from the last dose of non-myelosuppressive biological therapy and at least 4 weeks from the completion of radiation therapy.

• Patients must have no overt cardiac, gastrointestinal, pulmonary, or psychiatric disease.

Patients must be willing to travel to Pittsburgh to receive the vaccine. Visits: Every 3 weeks x 9, then every 6 weeks x 12 depending on response/side effects

Exclusion Criteria:

• Patients living outside of North America are not eligible.

• Patients must be off concurrent treatment or medications for at least 1 week including: Interferon (e.g. Intron-A®), allergy desensitization injections, growth factors (e.g. Procrit®, Aranesp®, Neulasta®), interleukins (e.g. Proleukin®), and any investigational therapeutic medication.

• Patients must not have a history of any immune system disorder or laboratory abnormality or any condition that could potentially alter immune function.

• Use of immunosuppressives within four weeks prior to study entry or anticipated use of immunosuppressive agents. Patients must be on no more than 0.1 mg/kg/day, max 4 mg/day dexamethasone for at least one week before study registration. Topical corticosteroids are acceptable.

• Patients with a known immune deficiency.

• Pregnancy or breastfeeding. Female patients who are post-menarchal must have a documented negative pregnancy test.

• Tetanus vaccine during therapy or within 1 week prior to enrollment.

• Patients who have received prior immunotherapy.

Related Conditions & MeSH terms

• Ependymoma

Intervention

Biological:
• HLA-A2 restricted synthetic tumor antigen

Drug:
• Imiquimod

Other:
• enzyme-linked immunosorbent assay

• flow cytometry

• immunohistochemistry staining method

• laboratory biomarker analysis

Locations

Country	Name	City	State
United States	Children's Hospital of Pittsburgh of UPMC	Pittsburgh	Pennsylvania

Sponsors (3)

Lead Sponsor	Collaborator
James Felker	National Cancer Institute (NCI), Solving Kids' Cancer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with unacceptable toxicity	Grade 3 or 4 non-hematological toxicities.	2 years
Secondary	Tumor-associated antigen-specific T-cell		2 years